These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31108199)

  • 1. Leveraging the entire cohort in drug safety monitoring: part 1 methods for sequential surveillance that use regression adjustment or weighting to control confounding in a multisite, rare event, distributed data setting.
    Nelson JC; Ulloa-Pérez E; Bobb JF; Maro JC
    J Clin Epidemiol; 2019 Aug; 112():77-86. PubMed ID: 31108199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulation study comparing exposure matching with regression adjustment in an observational safety setting with group sequential monitoring.
    Stratton KG; Cook AJ; Jackson LA; Nelson JC
    Stat Med; 2015 Mar; 34(7):1117-33. PubMed ID: 25510526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
    Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
    Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.
    Gagne JJ; Wang SV; Rassen JA; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):619-27. PubMed ID: 24788694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing performance of sequential analysis methods for active drug safety surveillance using observational data.
    Zhou X; Bao W; Gaffney M; Shen R; Young S; Bate A
    J Biopharm Stat; 2018; 28(4):668-681. PubMed ID: 29157113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs.
    Wang SV; Schneeweiss S; Maclure M; Gagne JJ
    Am J Epidemiol; 2014 Sep; 180(6):636-44. PubMed ID: 25086050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance.
    Silva IR; Kulldorff M
    Biometrics; 2015 Sep; 71(3):851-8. PubMed ID: 26011024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
    Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
    J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A primer of drug safety surveillance: an industry perspective. Part III: Managing adverse-event data.
    Allan MC
    J Pharm Technol; 1992; 8(6):259-73. PubMed ID: 10122649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel statistical tools for monitoring the safety of marketed drugs.
    Almenoff JS; Pattishall EN; Gibbs TG; DuMouchel W; Evans SJ; Yuen N
    Clin Pharmacol Ther; 2007 Aug; 82(2):157-66. PubMed ID: 17538548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity.
    Maro JC; Brown JS; Dal Pan GJ; Kulldorff M
    Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):839-48. PubMed ID: 24700557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utilization and challenges of Japan's MID-NET
    Yamada K; Itoh M; Fujimura Y; Kimura M; Murata K; Nakashima N; Nakayama M; Ohe K; Orii T; Sueoka E; Suzuki T; Yokoi H; Ishiguro C; Uyama Y;
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):601-608. PubMed ID: 30945387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.
    Cook AJ; Tiwari RC; Wellman RD; Heckbert SR; Li L; Heagerty P; Marsh T; Nelson JC
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():72-81. PubMed ID: 22262595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Synthesis of Current Surveillance Planning Methods for the Sequential Monitoring of Drug and Vaccine Adverse Effects Using Electronic Health Care Data.
    Nelson JC; Wellman R; Yu O; Cook AJ; Maro JC; Ouellet-Hellstrom R; Boudreau D; Floyd JS; Heckbert SR; Pinheiro S; Reichman M; Shoaibi A
    EGEMS (Wash DC); 2016; 4(1):1219. PubMed ID: 27713904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.
    Xu Y; Zhou X; Suehs BT; Hartzema AG; Kahn MG; Moride Y; Sauer BC; Liu Q; Moll K; Pasquale MK; Nair VP; Bate A
    Drug Saf; 2015 Aug; 38(8):749-65. PubMed ID: 26055920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA's monitoring of postmarketing studies probed.
    Young D
    Am J Health Syst Pharm; 2006 Aug; 63(16):1485-6. PubMed ID: 16896075
    [No Abstract]   [Full Text] [Related]  

  • 18. Bayesian safety surveillance with adaptive bias correction.
    Bu F; Schuemie MJ; Nishimura A; Smith LH; Kostka K; Falconer T; McLeggon JA; Ryan PB; Hripcsak G; Suchard MA
    Stat Med; 2024 Jan; 43(2):395-418. PubMed ID: 38010062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A primer of drug safety surveillance: an industry perspective. Part I: Information flow, new drug development, and federal regulations.
    Allan MC
    J Pharm Technol; 1992; 8(4):162-7. PubMed ID: 10121011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An MCEM Framework for Drug Safety Signal Detection and Combination from Heterogeneous Real World Evidence.
    Xiao C; Li Y; Baytas IM; Zhou J; Wang F
    Sci Rep; 2018 Jan; 8(1):1806. PubMed ID: 29379048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.